📝 3B BlackBio Dx Ltd — results explained
Quarter ended June 2026 (Q1 FY27)
3B BlackBio Dx Ltd reported revenue of ₹33 crore for the quarter ended June 2026 (Q1 FY27), up 50.7% from ₹22 crore in the same quarter last year, and down 5.5% sequentially over the March 2026 quarter.
Net profit fell 29.0% year-on-year to ₹9 crore, from ₹13 crore. Earnings per share (EPS) came in at ₹10.48.
Operating profit stood at ₹9 crore — an operating margin (OPM) of 25.4%, compared with 53.2% in the year-ago quarter.
Full year and trailing twelve months
For the full year FY26, 3B BlackBio Dx Ltd posted revenue of ₹142 crore, a growth of 47.1% over FY25, with a net profit of ₹60 crore (up 25.7% year-on-year).
On a trailing-twelve-month (TTM) basis, revenue stands at ₹153 crore with a net profit of ₹56 crore.
Valuation snapshot
At the current price of ₹1,296.00, 532067 has a market capitalisation of ₹1,166 crore and a trailing P/E of about 20.7.
Within the Healthcare Service Provider industry, it is the 2nd-largest of the 20 companies we track by market value.
Shareholding pattern
As of Jun 2026, promoters held 40.95%, foreign institutional investors (FIIs) 2.50%, domestic institutional investors (DIIs) 2.15%, public shareholders 54.40% of 3B BlackBio Dx Ltd.